Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21986862 | 0.88 | CYP4F2 (0.33) | CYP4F2CYP4A11CYP2C19NPC1RAB9A | |
| SCHEMBL21986817 | 0.88 | CYP4F2 (0.35) | CYP4F2CYP4A11CYP2C19NPC1RAB9A | |
| SCHEMBL21986849 | 0.75 | FGFR1 (0.34) | CYP2C19NPC1RAB9AMEN1KMT2A | |
| SCHEMBL21986745 | 0.75 | ATR (0.33) | CYP2C19TSHRATR | |
| SCHEMBL21986866 | 0.75 | CYP4F2 (0.37) | CYP4F2CYP4A11NPC1RAB9AMEN1 | |
| SCHEMBL21986776 | 0.75 | CYP4F2 (0.37) | CYP4F2CYP4A11MEN1KMT2AATR | |
| SCHEMBL21986700 | 0.74 | ATR (0.36) | CYP4F2CYP4A11NPC1RAB9AMEN1 | |
| SCHEMBL21986808 | 0.70 | SLC6A3 (0.39) | YTHDC1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL11911433 | 0.66 | ABL1 (0.38) | CYP4F2CYP4A11CYP2C19NPC1RAB9A | |
| SCHEMBL21986741 | 0.65 | CYP4F2 (0.37) | CYP4F2CYP4A11NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3660003-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-11713311-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-01 | — | — | US | disclosed |
| US-20220388995-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-08 | — | — | US | disclosed |
| US-11230541-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-25 | — | — | US | disclosed |
| US-20200231579-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-23 | — | — | US | disclosed |
| EP-3660003-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230541-B2 | Heterocyclic compound | GRIN1, GRIN2A, GRIN2B | CYP4F2 4162/4885CYP4A11 3116/4885YTHDC1 4678/4885 |
| US-20200231579-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRIN2A, GRIN2B | CYP4F2 4162/4885CYP4A11 3116/4885YTHDC1 4678/4885 |
| US-11713311-B2 | Heterocyclic compound | GRIN1, GRIN2A, GRIN2B | CYP4F2 4162/4885CYP4A11 3116/4885YTHDC1 4678/4885 |
| US-20220388995-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRIN2A, GRIN2B | CYP4F2 4162/4885CYP4A11 3116/4885YTHDC1 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.